Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Survival: 13.2 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Temodar
Country: United States
City/State/Province: Houston, Texas
Hospital: University of Texas MD Anderson Cancer Center
Journal: Link
Date: 10/2002

Patients: This Phase II study included a total of 57 patients - twenty-one newly diagnosed patients with anaplastic astrocytoma and thirty-six newly diagnosed patients with glioblastoma multiforme.

Treatment: The treatment consisted of a chemotherapy drug, temozolomide (temodar) followed by radiation therapy.

Toxicity: Toxicity was mainly hematological (thrombocytopenia and neutropenia). Grade 3 and 4 adverse reactions also included: constipation (grade 3), nausea (grade 3), anemia (grade 4), ataxia (grade 3), impaired cognition (grade 3), convulsions (grade 3 and 4), speech disorder (grade 3), behavior disorder (grade 3), altered mental status (grade 3), somnolence (grade 3), suicide attempt (grade 4), hypotension (grade 3), asthenia (grade 3), back pain (grade 3), headache (grade 3), weight decrease (grade 3), syncope (grade 3), bradycardia (grade 4), bilirubinemia (grade 3), hyperglycemia (grade 3), apnea (grade 3), basalcell carcinoma (grade 3), urinary tract infection (grade 3), and intreacranial hemorrhage (grade 3). Most of these adverse events effected only single patients.

Results: For adult glioblastoma multiforme patients, median overall survival was 13.2 months.

Support: This study was supported by Schering-Plough. This pharmaceutical company also markets temozolomide, the drug being tested in this study.

E-mail to a Friend More Information